20th Annual Highlights of the 2021 San Antonio Breast Cancer Symposium
Continuing Medical Education (CME) Programs On-Demand
Presented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education, these enduring materials are designed to help clinicians translate the data from key presentations from the 2021 San Antonio Breast Cancer Symposium into practice.
View speakers from Fox Chase and Penn Medicine’s Abramson Cancer Center as they present information on the treatment of breast cancer, including screening, prevention, local control, chemotherapy, hormonal therapy, and advances in breast cancer biologics and their impact on breast cancer management.
INTENDED AUDIENCE
The program is designed for medical, radiation and surgical oncologists, gynecologists, radiologists, and primary care physicians. Other physician specialties, nurses, advanced practice clinicians and healthcare professionals involved in the treatment of patients with breast cancer may find the program beneficial.
Local Control
Richard J. Bleicher, MD, FACS
Professor, Department of Surgical Oncology; Leader, Breast Cancer Program; Director, Breast Fellowship Program
Fox Chase Cancer Center
Temple Health designates this enduring material
for a maximum of .5 AMA PRA Category 1 Credit™.
Adjuvant Therapy
Kristen D. Whitaker, MD, MS
Former Assistant Professor, Department of Clinical Genetics and Department of Hematology/Oncology
Fox Chase Cancer Center
Temple Health designates this enduring material
for a maximum of .5 AMA PRA Category 1 Credit™.
ER+
Angela DeMichele, MD, MSCE
Jill & Alan Miller Endowed Chair in Breast Cancer Excellence; Professor of Medicine; Co-Leader, Breast Cancer Program; Co-Director, 2-PREVENT Translational Center of Excellence
Penn Medicine's Abramson Cancer Center
Temple Health designates this enduring material
for a maximum of .5 AMA PRA Category 1 Credit™.
HER2+
Lori J. Goldstein, MD, FASCO
Program Director
Professor Emerita, Department of Hematology/Oncology
Fox Chase Cancer Center
Temple Health designates this enduring material
for a maximum of .5 AMA PRA Category 1 Credit™.
TNBC and Immunotherapy
Elias Obeid, MD, MPH
Interim Chief, Division of Breast Medical Oncology; Assistant Professor, Department of Clinical Genetics and Department of Hematology/Oncology; Director, Breast, Ovarian, and Prostate Cancer Risk Assessment
Fox Chase Cancer Center
This enduring material is not eligible for AMA PRA Category 1 Credit™.
Molecular Genetics
Susan M. Domchek, MD
Executive Director, Basser Center for BRCA; Director, MacDonald Cancer Risk Evaluation Center; Basser Professor in Oncology
Penn Medicine's Abramson Cancer Center
Temple Health designates this enduring material
for a maximum of .5 AMA PRA Category 1 Credit™.
ACCREDITATION STATEMENT
Temple Health is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians.